

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*			2. Issuer Name and Ticker or Trading Symbol			5. Relationship of Reporting Person(s) to Issuer (Check all applicable)		
<u>Mahatme Sandesh</u>			<u>Sarepta Therapeutics, Inc. [SRPT]</u>			Director 10% Owner		
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year)			X Officer (give title below) Other (specify below)		
215 FIRST STREET, SUITE 415			10/24/2018			EVP, CFO & CBO		
(Street)			4. If Amendment, Date of Original Filed (Month/Day/Year)			6. Individual or Joint/Group Filing (Check Applicable Line)		
CAMBRIDGE MA 02142						X Form filed by One Reporting Person		
(City)	(State)	(Zip)				Form filed by More than One Reporting Person		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	10/24/2018		M ⁽¹⁾		9,596	A	\$23.85	48,381	D	
Common Stock	10/24/2018		M ⁽¹⁾		39,006	A	\$13.9	87,387	D	
Common Stock	10/24/2018		M ⁽¹⁾		29,080	A	\$13.71	116,467	D	
Common Stock	10/24/2018		M ⁽¹⁾		11,718	A	\$13.71	128,185	D	
Common Stock	10/24/2018		S ⁽¹⁾		107,524	D	\$127.74 ⁽²⁾	20,661	D	
Common Stock	10/24/2018		G ⁽³⁾	V	12,012	D	\$0.00	8,649	D	
Common Stock	10/24/2018		G ⁽³⁾	V	12,012	A	\$0.00	12,012	I	By wife

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Stock Option (right to buy)	\$23.85	10/24/2018		M ⁽¹⁾			9,596	(4)	11/05/2022	Common Stock	9,596	\$0.00	116,009	D	
Stock Option (right to buy)	\$13.9	10/24/2018		M ⁽¹⁾			39,006	(5)	02/27/2025	Common Stock	39,006	\$0.00	17,860	D	
Stock Option (right to buy)	\$13.71	10/24/2018		M ⁽¹⁾			29,080	(6)	02/28/2026	Common Stock	29,080	\$0.00	7,899	D	
Stock Option (right to buy)	\$13.71	10/24/2018		M ⁽¹⁾			11,718	(7)	02/28/2026	Common Stock	11,718	\$0.00	12,873	D	

Explanation of Responses:

1. These trades were made pursuant to a Rule 10b5-1 trading plan.

2. The shares were sold in multiple transactions at prices ranging from \$120.87 to \$134.39, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price with the range set forth herein.
3. This transaction involved a gift of securities by the reporting person to his wife.
4. The option to purchase shares is fully vested.
5. The option vests based on time criteria (25% of the total option on 2/27/2016 and 1/48th of the total option in equal monthly installments thereafter).
6. Half of the total options granted began vesting when the FDA provided marketing approval for eteplirsen on 9/19/2016 and the other half of the total options granted began vesting when Sarepta Therapeutics, Inc. filed a Marketing Authorization Application with the European Medicines Agency on 11/30/2016. Vesting of the options allocated to the achievement of each goal is as follows: (i) 50% of the options allocated to the achieved goal vested immediately upon achievement of the performance condition (25% of the total performance-based options granted) and (ii) the remaining 50% of the options allocated to the achieved goal (25% of the total performance-based options granted) vest over four years. 25% of the remaining options vested on the first year anniversary of the grant date, or 2/28/2017 and 1/48th of the remaining options vests monthly thereafter.
7. The option vests based on time criteria (25% of the total option on 2/29/2017 and 1/48th of the total option in equal monthly installments thereafter).

Remarks:

/s/ David Tyrone Howton, as
attorney-in-fact for Sandesh 10/26/2018
Mahatme

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.